CLOs on the Move

RAPT Therapeutics

www.rapt.com

 
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.rapt.com
  • 561 Eccles Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.489.9000

Executives

Name Title Contact Details
Michael Listgarten
 General Counsel Profile
Jennifer Nicholson
 Senior Vice President of Regulatory Affairs and Quality Assurance Profile

Similar Companies

Vitaflo USA

Vitaflo USA is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exagen Diagnostics Inc.

Exagen Diagnostics Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

scientist.com

Scientist.com is the world's largest online research marketplace.

Neuron23

Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.

VelosBio

VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.